Literature DB >> 2451190

Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features.

J A Kaye1, C May, E Daly, J R Atack, D J Sweeney, J S Luxenberg, A D Kay, S Kaufman, S Milstien, R P Friedland.   

Abstract

We measured monoamine metabolites and biopterin in the CSF of 37 patients with dementia of the Alzheimer type (DAT), with or without extrapyramidal signs, and in 14 age-matched healthy controls. Compared with concentrations in DAT and controls, the concentrations of homovanillic acid (HVA) and biopterin were significantly decreased in DAT with extrapyramidal signs (EDAT). CSF 3-methoxy-4-hydroxy-phenethyleneglycol and 5-hydroxyindoleacetic acid did not differ significantly among these groups. Age at onset of dementia was positively correlated with CSF HVA (r = 0.49, p less than 0.05). The two dementia groups did not differ significantly in the extent of ventricular dilation as measured by quantitative CT, but EDAT patients had lower Mini-Mental State Examination scores than did DAT patients. When patients were matched for age and dementia severity, CSF HVA and biopterin concentrations remained significantly lower in EDAT than in DAT patients. These results indicate that EDAT patients form a distinct subgroup of DAT with evidence of central monoamine dysfunction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451190     DOI: 10.1212/wnl.38.4.554

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Alzheimer's disease.

Authors:  M Rossor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

Review 2.  At the interface of sensory and motor dysfunctions and Alzheimer's disease.

Authors:  Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

3.  Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.

Authors:  G L Corona; M L Cucchi; P Frattini; G Santagostino; S Schinelli; A Romani; A Pola; F Zerbi; F Savoldi
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

4.  Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease.

Authors:  M B Schapiro; P Pietrini; C L Grady; M J Ball; C DeCarli; A Kumar; J A Kaye; J V Haxby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.